Close

Halozyme Therapeutics (HALO) PT Lowered to $62 at BMO Capital Nov 3, 2021 07:32AM
Halozyme Therapeutics (HALO) PT Raised to $66 at BMO Capital Aug 10, 2021 09:04AM
Halozyme Therapeutics (HALO) PT Raised to $66 at BMO Capital Feb 24, 2021 08:57AM
Halozyme Therapeutics (HALO) PT Raised to $65 at BMO Capital Jan 25, 2021 07:24AM
Halozyme Therapeutics (HALO) PT Raised to $56 at BMO Capital Jan 12, 2021 06:32AM


Nov 23, 2020 03:21PM Halozyme Therapeutics (HALO) PT Raised to $47 at BMO Capital, Following Business Update And Guidance
Jan 14, 2020 12:54PM Halozyme Therapeutics (HALO) PT Raised to $25 at BMO Capital, Following FY 2020 Guidance
Jan 9, 2020 07:02AM UPDATE: BMO Capital Upgrades Halozyme Therapeutics (HALO) to Outperform
Nov 4, 2019 12:52PM Halozyme Therapeutics (HALO) PT Lowered to $16 at BMO Capital
Nov 27, 2018 07:42AM Halozyme Therapeutics (HALO) PT Lowered to $17 at BMO Capital
Nov 7, 2018 09:00AM Halozyme Therapeutics (HALO) PT Lowered to $19 at BMO Capital
Aug 8, 2018 08:26AM Halozyme Therapeutics (HALO) PT Raised to $21 at BMO Capital
Aug 8, 2018 06:59AM Halozyme Therapeutics (HALO) PT Raised to $21 at BMO Capital
Feb 21, 2018 08:42AM Halozyme Therapeutics (HALO) PT Raised to $19 at BMO Capital
Jan 17, 2018 06:23AM Weakness Expected in Halozyme Therapeutics (HALO) as SWOG mFFOX Combo Too Toxic for PEGPH20 Benefit - BMO
Nov 15, 2017 08:00AM Halozyme Therapeutics To Participate In Upcoming Healthcare Conferences
Apr 17, 2017 04:04AM BMO Capital Starts Halozyme Therapeutics (HALO) at Market Perform
Feb 1, 2016 10:38AM Notable Analyst Rating Changes 2/1: (JOY) (PFPT) (VRTX) Upgraded; (ARR) (GPC) (AIG) Downgraded
Apr 20, 2015 07:51AM Halozyme Therapeutics (HALO) Bullish Stance Reiterated at BMO Capital Amid Positive AACR Update
Mar 3, 2015 07:23AM Halozyme Therapeutics (HALO) PT Raised to $26 at BMO Capital
Jan 7, 2015 02:47PM Halozyme Therapeutics (HALO) Surges Following Impressive Data for PEGPH20 in Pancreatic Cancer from Investor Day
May 13, 2014 06:26AM Halozyme Therapeutics (HALO) Q1 Report 'Solid' on Multiple Fronts - BMO Capital
Apr 4, 2014 09:40AM BMO Capital Defends Halozyme Therapeutics (HALO); Buy on Weakness
Feb 5, 2014 07:41AM Halozyme Therapeutics (HALO) Prices 7.7M Offering at $13/Share
Sep 3, 2013 09:34AM Pre-Open Stock Movers 9/3: (NOK) (HALO) (TU) Higher; (CYTK) (STP) (MSFT) Lower (more...)
Jan 14, 2013 12:50PM Unusual 11 Mid-Day Movers 01/14: (AZK) (HALO) (CXPO) Higher; (TELK) (BIOL) (NTE) Lower
Jan 14, 2013 09:32AM StreetInsider.com Pre-Open Movers 01/14: (VRNT) (FRAN) (RIG) Higher; (NTE) (AAPL) (CRUS) Lower (more...)
Jan 14, 2013 07:43AM BMO Capital Upgrades Halozyme Therapeutics (HALO) to Outperform
Apr 16, 2012 12:01PM BMO Cuts Halozyme (HALO) to Market Perform Following FDA's Request for More Info on HyQ Application
Sep 7, 2011 05:54PM BMO Starts Biotech Stocks: AMGN, HGSI, REGN, CELG at Outperform, AMLN, GILD, ARNA at Market Perform, BIIB at Underperform